Hamza Mohamed

Hamza Mohamed

Auto-generated profile, based on publicly available information

Hamza Mohamed

Faculty of Medicine, Assiut University, Assiut, Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
BIBaha’ Aldeen Bani Irshid
Baha’ Aldeen Bani Irshid
TMTarek Mohamed
Tarek Mohamed
MDMohammad Ghassab Deameh
Mohammad Ghassab Deameh
HEHamza Elhashamy
Hamza Elhashamy
MRMohamed Ramez
Mohamed Ramez
AAAhmed Abdelhalim
Ahmed Abdelhalim

15 January 2026 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
TMTarek Mohamed
Tarek Mohamed
BIBaha’ Aldeen Bani Irshid
Baha’ Aldeen Bani Irshid
HEHamza Elhashamy
Hamza Elhashamy
MDMohammad Ghassab Deameh
Mohammad Ghassab Deameh
HMHamza Mohamed
Hamza Mohamed
MRMohamed Ramez
Mohamed Ramez
Purpose: To evaluate the impact of extended versus nonextended perioperative antibiotic prophylaxis (PAP) on reducing postoperative complications and hospital stays in patients undergoing radical cystectomy and urinary diversion. Methods: We conducted this systematic review and meta-analysis in accordance with the PRISMA guidelines. A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and the Cochrane Library for studies comparing short-term (≤ 24 h) and extended (≥ 24 h) PAP in patients undergoing radical cystectomy and urinary diversion. The primary outcomes were surgical site infections (SSIs), urinary tract infections (UTIs), and length of hospital stay. The statistical analysis was performed via RevMan version 5.3. The results are presented as risk ratios (RRs) and mean differences (MDs). Results are presented as risk ratios (RRs) and mean differences (MDs). The quality of evidence was assessed using the GRADE methodology. Results: A total of 214 studies were screened. Four studies involving 680 patients were included. No significant differences were detected between short-term and extended PAP in terms of SSIs (RR = 0.71 [95% CI 0.43–1.17]; P = 0.18]), febrile UTIs (RR = 1.19 [95% CI 0.91–1.56]; P = 0.20]), or length of hospital stay (MD = 0.76 days [95% CI [-2.72, 4.25]; P = 0.67]). Conclusion: No significant difference was observed between 24-h and extended PAP for reducing postoperative complications after radical cystectomy and urinary diversion. Short-term PAP is a reliable and effective strategy and is recommended as the standard practice for reducing antimicrobial resistance and improving postoperative outcomes.

Verified
Journal Article
Open access
PDF file
MDMohammad Ghassab Deameh
Mohammad Ghassab Deameh
WSWafika A. M. SulimanThaher
Wafika A. M. SulimanThaher
RARahma AlMari
Rahma AlMari
Omar MustafaOmar Mustafa
Omar Mustafa
QAQutiba Alwreikat
Qutiba Alwreikat
Mohammed ShahaitMohammed Shahait
Mohammed Shahait
Background/Objectives: Prostate biopsy is essential for diagnosing prostate cancer. Social determinants of health (SDOH), including socioeconomic status, race, occupation, education, and environment, affect access, outcomes, and quality of life. Recognizing disparities from technology access to complications is crucial for equitable care. A systematic review examined how SDOH impacts biopsy access, technology, and complications. Methods: A systematic search of PubMed, Web of Science, and Scopus was performed to identify eligible studies published through February 2026. We included studies that evaluated the association between one or more SDOHs and prostate biopsy. Relevant outcomes included biopsy utilization, use of specific biopsy technologies (e.g., magnetic resonance imaging (MRI)-guided, transperineal), and post-procedural complications. Results: Nine observational studies met the inclusion criteria. The findings revealed disparities across three key domains. First, access to advanced biopsy technology was uneven. Four studies showed that Black men were significantly less likely than White men to receive MRI-guided biopsies. Additionally, post-biopsy outcomes showed that Black and Hispanic men faced significantly higher rates of post-biopsy infection and hospitalization compared to White men. Lastly, patients in rural areas, those in public hospitals, and individuals with lower socioeconomic status demonstrated reduced access to modern techniques, including MRI-guided or transperineal biopsy. Conclusions: Social and economic factors influence who receives a prostate biopsy and who has access to advanced technologies. Minority and low-income patients face diagnosis barriers and higher complication rates, highlighting systemic inequities. The healthcare system often rewards access over need, and without bold policy changes, gaps in technology and resources will worsen, moving us further from truly equitable prostate cancer care.

6 November 2026 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
MRMohamed Ramez
Mohamed Ramez
MMMostafa M Mostafa
Mostafa M Mostafa
HMHamza Mohamed
Hamza Mohamed
MDMohammad Ghassab Deameh
Mohammad Ghassab Deameh
TMTarek Mohamed
Tarek Mohamed
OROmer A. Raheem
Omer A. Raheem
Background: Sexual dysfunction remains highly prevalent among men and significantly impacts quality of life. Peptides are short chains of amino acids designed to mimic endogenous signaling molecules and modulate a variety of physiological pathways. Aim: To systematically review the available human evidence evaluating the effects of peptide and peptide-derived therapies on male sexual function, reproductive hormones, and semen parameters. Methods: A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Web of Science were searched. Eligible studies included randomized controlled trials, crossover studies, prospective clinical studies, and experimental physiological studies evaluating peptide-based interventions in adult men. Outcomes: Outcomes of interest included erectile function, sexual desire, orgasmic and ejaculatory outcomes, reproductive hormones, semen parameters, and adverse events. Results: Twelve studies comprising 372 male participants met inclusion criteria. Investigated peptides included melanocortin receptor agonists (PT-141/bremelanotide and Melanotan II), kisspeptin analogues, and oxytocin. Melanocortin receptor agonists demonstrated the most consistent improvements in erectile function, producing significant increases in penile rigidity and erectile duration in healthy men and men with erectile dysfunction, including sildenafil non-responders. Kisspeptin increased gonadotropin secretion, enhanced sexual brain processing, and improved penile tumescence and measures of sexual desire in men with hypoactive sexual desire disorder. Oxytocin showed mixed effects, with potential benefits on orgasm intensity, sexual satisfaction, and partner interaction, but no consistent improvements in erectile function, ejaculation latency, or semen parameters. Clinical Implications: Peptide-based interventions may influence male sexual health through distinct peripheral, central, endocrine, and relational mechanisms, offering potential adjuncts or second-line alternatives for men who have failed or are intolerant of first-line pharmacotherapy. Strengths and Limitations: Strengths include the synthesis of human clinical evidence across multiple peptide classes and principal domains of male sexual function. Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies. Conclusion: Melanocortin receptor agonists currently have the strongest evidence for improving erectile outcomes, while kisspeptin represents a promising emerging therapy for sexual desire and reproductive endocrine modulation. However, the evidence base remains limited, and further studies are required before these therapies can be incorporated into routine clinical practice.

29 July 2025 in Arab Journal of Urology
Verified
Journal Article
Open access
HEHamza Elhashamy
Hamza Elhashamy
TMTarek Mohamed
Tarek Mohamed
BIBaha’ Aldeen Bani Irshid
Baha’ Aldeen Bani Irshid
MDMohammad Ghassab Deameh
Mohammad Ghassab Deameh
MRMohamed Ramez
Mohamed Ramez
This study aims at assessing the effectiveness of using prophylactic mesh for the prevention of Parastomal hernia (PSH) after cystectomy and ileal conduit. PRISMA statement guidelines were followed. A comprehensive literature search was conducted across PubMed, MEDLINE, Cochrane Library, and Embase databases. The primary outcomes analyzed were operation time, clinical hernia, radiological hernia, and complications classified as greater than or less than 3 on the Clavien-Dindo scale. Three RCTs with a total number of 782 patients were included. The occurrence of clinical hernia significantly favored the mesh group, with a risk ratio (RR) of 0.50 (p < 0.002). However, the occurrence of radiological hernia showed no significant difference between groups, with an RR of 0.72 (p = 0.10). The analysis of operation time significantly favored the no mesh group, with a mean difference (MD) of −28.56 minutes (p < 0.002), indicating shorter operation times compared to the mesh group. Regarding complications, no significant differences were observed between the mesh and no mesh groups. For Clavien–Dindo Grade ≥3 complications, the RR was 1.11 (p = 0.42), and for Clavien–Dindo Grade <3 complications, the RR was 1.15 (p = 0.36) Prophylactic mesh significantly reduces the incidence of PSH following ileal conduit. However, it does not significantly affect radiological hernia rates or complication rates. Despite longer operation times, its use offers a clear benefit in preventing PSH without substantially increasing complications.

21 July 2026 in Canadian Urological Association Journal
Verified
Journal Article
Open access
PDF file
MMMostafa M. Mostafa
Mostafa M. Mostafa
AAAbdelrahman Abdelshafi
Abdelrahman Abdelshafi
HMHamza Mohamed
Hamza Mohamed
ADAmr E. Darwish
Amr E. Darwish
Introduction: Urinary incontinence (UI) remains a distressing complication following surgical treatment of benign prostatic hyperplasia (BPH). Although postoperative UI is well described, few prospective studies have distinguished predictors of stress urinary incontinence (SUI) from those of urge urinary incontinence (UUI). Methods: In this prospective cohort study (July 2022–July 2024), 133 men undergoing bipolar transurethral resection of the prostate (B-TURP) or bipolar enucleation of the prostate (BipolEP) were followed-up for ≥ 1 year. Preoperative and intraoperative variables were evaluated using univariate testing and multivariable logistic regression to identify independent predictors of persistent SUI and UUI. Results: SUI occurred in 20.3% of patients and was independently associated with older age and use of the enucleation technique with additional univariate associations observed for larger prostate volume, lower baseline Qmax, and greater resected tissue weight. UUI occurred in 15.8% and was independently predicted by higher IPSS scores and preoperative detrusor overactivity with univariate association also noted for older age; no intraoperative factor predicted UUI. Conclusions: SUI is primarily driven by anatomical and surgical factors, whereas UUI reflects underlying bladder dysfunction. Differentiating these predictive profiles supports individualized patient counseling, procedural planning, and preoperative risk stratification for men undergoing transurethral prostatectomy.